

# Intestinal Microbiome, Small Intestinal Bacterial Overgrowth and Inflammatory Bowel Diseases - What are the Connections?

M. ANDREI<sup>1</sup>, T. NICOLAIE<sup>1</sup>, ADRIANA STOICESCU<sup>1</sup>,  
ADRIANA TEIUȘANU<sup>1</sup>, Ș. GOLOGAN<sup>1</sup>, M. DICULESCU<sup>2</sup>

<sup>1</sup>Department of Gastroenterology, Hepatology and Digestive Endoscopy,  
Elias Emergency Hospital, Bucharest, Romania

<sup>2</sup>Department of Gastroenterology, Hepatology, Digestive Endoscopy,  
Fundeni Clinical Institute, Bucharest, Romania

**ABSTRACT:** IBD (inflammatory bowel diseases) represent chronic idiopathic inflammatory diseases, prone to relapse in the digestive tract; it is estimated that they result from the interaction of the intestinal microbiome with the intestinal immune system. The inflammatory microbiome exerts multiple beneficial roles. Perhaps the central element to developing IBD is dysbiosis; there is still an incompletely established association between intestinal microbiome changes in patients with IBD and SIBO (small intestinal bacterial overgrowth). Influencing the intestinal microbiome may play an adjuvant therapeutic role in the treatment of IBD. We present a synthesis of the connections between the entities mentioned above.

**KEYWORDS:** *inflammatory bowel disease, small intestinal bacterial overgrowth, intestinal microbiota*

## Intestinal Microbiome

The small intestine is, from a microbiological point of view, a transitional area between the stomach (under  $10^3$  colony forming units/ ml) and colon (approximately  $10^{12}$  microorganisms per gram of colonic content), which comprises more than 1000 different species of microorganisms.

The number of microbial species present in the human gastrointestinal tract is estimated to range between 1000-1150; at the same time, there are at least 160 species coexisting in every individual [1,2].

The intestinal microbiome presents multiple roles - summarized in Table 1.

**Table 1. Beneficial roles of the intestinal microbiome**

• removal of undigested food elements
• removal of xenobiotics
• synthesis of vitamins/micronutrients (vitamin K, folic acid, biotin)
• signalling mechanisms for restoring the mucosal barrier
• secretion of antimicrobial substances (bacteriocins and lactic acid)
• to decrease the risk of colonization with pathogenic bacteria
• determination of physiological statuses [2,3,4]
• biological transformation of bile salts [5]
• adjuvant in the metabolism of certain drugs (sulfasalazine, digoxin) [5]

There is some data in the literature on differences between the microbiome of obese individuals and individuals with normal body weight, which could lead to differences in caloric extraction from ingested food [5,6,7].

The most important species are Firmicutes and Bacteroidetes, Proteobacteria and Actinobacteria, Verucomicrobia and Fusobacteria [2,8]. Some of these species are considered to exert anti-inflammatory and anti-tumorigenic roles, as well as inhibition of pathogens: bacteria producing butyrate (*Faecalibacterium prausnitzii*, *Roseburia* spp) and those producing lactic acid (*Lactobacillus* and *Bifidobacterium*) [2,9].

## SIBO (small intestinal bacterial overgrowth)

SIBO is characterized by bacterial overpopulation of the small bowel [10] or by alterations in the type and ratio of these microorganisms [11]. The classic definition is represented by the presence of at least  $10^5$  CFU/ml of intestinal aspirate.

The spectrum of clinical manifestations is very variable; from nonspecific signs and symptoms (bloating, unorganized abdominal pain syndrome, excessive flatulence, nausea, abdominal cramps) to severe consequences due to diarrhoea and malabsorption (hypoalbuminemia and underweight / weight loss) [12,13], fat soluble vitamin deficiencies: osteomalacia and hypocalcaemia secondary to

vitamin D deficiency [14,15], megaloblastic anaemia secondary to vitamin B12 deficiency [14,16], iron deficiency anaemia (by an incompletely established mechanism). The clinical significance of the symptoms described by patients (especially forms that do not present a significant biological impact) is difficult to determine, as many of the manifestations reported overlap those of irritable bowel syndrome; some reports or studies indicate the presence of a single symptom, while others describe up to 10-20 symptoms [14].

Regarding the diagnosis of SIBO, a recent systematic review [17] concluded that there is no gold-standard diagnostic test. The following diagnostic modalities are the ones available:

- Some authors consider that the best diagnostic modality is represented by intestinal fluid aspirate from the proximal jejunum, quantitative cell counting and culture [18]. Presence of over  $10^5$  CFU/ml Gram negative coliform bacteria or strictly anaerobic bacteria is considered a defining criterion of SIBO [19]. However, this technique has several limitations, reducing its practical application: invasive, low availability, time-consuming, expensive, difficult transport and handling, risk of oral bacteria contamination of the duodenal aspirate, possibility of overlooking a SIBO with distal site [14].
- Empirical antibiotic treatment followed by secondary follow-up of symptom resolution [11]. There is no standardized approach in terms of the type of antibiotic used, of the doses administered or period of administration.
- Respiratory tests. They are based on the ability of the intestinal bacterial flora to metabolize an exogenous substrate (glucose, lactulose, D-xylose), producing gases such as CO<sub>2</sub>, methane or hydrogen.

More commonly used is the hydrogen glucose breath test (HGBT). Anaerobic bacteria preferentially metabolize carbohydrate molecules. Secondary to this fermentation, result: (a) *short-chain fatty acids - SCFA* (water is retained in the intestines by a phenomenon of osmotic gradient, which causes diarrhoea); (b) *hydrogen* crossing the intestinal wall reaches the general circulation, and is removed as part of the breath volume; (c) *carbon dioxide*. The hydrogen expired is measured in ppm (parts per million) from exhaled air using precise and reliable mobile devices [20]. The positive

diagnostic criteria for HGBT is represented by an increase of over 12 ppm compared to the base value after administration of 50 g glucose during the test, which lasts 2 hours [11]. Compared with aspirate and microbiological culture methods, HGBT has a sensitivity of 62% and specificity of about 82% [21].

The breath test also has several limitations: it requires a low-fibre diet for at least 24 hours before the procedure, smoking and exercise can affect its accuracy, antibiotics and laxatives should be avoided, differences in luminal pH can affect carbohydrate metabolism, rapid transit or delay in gastric emptying may generate false results [14].

## Intestinal Microbiome and IBD

IBD (ulcerative colitis-UC and Crohn's Disease-CD) are chronic idiopathic diseases, prone to relapse in the digestive tract, and considered at the moment to be a result of the interaction between intestinal microbiome and intestinal immune system [22,23]. The composition of the intestinal microbiome influences susceptibility to develop IBD [24].

There is important evidence on the involvement of the intestinal microbiome in the pathogenesis of IBD; experimental findings that mice lacking intestinal germs do not develop severe colitis come to support this hypothesis [25].

Dysbiosis (altering the intestinal microbiome ratio) is probably central to developing IBD [26]. In IBD, microbiome diversity is limited.

Intestinal microbiome changes in IBD and some consequences are represented in Table 2.

Pathogenic microorganisms associated with IBD are:

*Mycobacterium avium paratuberculosis (MAP)*-can be isolated from water, milk and meat and is resistant to pasteurization. It seems that the incidence of positive samples of MAP is no higher in CD than in the control population if we refer to faeces tests, but is significantly increased when the comparison is made by biopsy of the distal ileum or colon [2,37,38]. However, the role of MAP in the aetiology of inflammatory diseases remains uncertain.

*Helicobacter* seems to be negatively associated with IBD [26]. *Hepaticus*, *bilis*, *trogontum* and *rodentium* species apparently induce an immune response against commensal bacteria, and secondary immune-mediated intestinal inflammation [26,39].

**Table 2. The special features of the intestinal microbiome in IBD**

• Decrease of species of Firmicutes (Clostridium cluster IX and IV)
▪ Associated with reducing the amount of SCFA (of which butyrate has the ability to inhibit pro-inflammatory cytokines)
▪ Decrease of <i>Faecalibacterium prausnitzii</i> was recently found in Crohn's disease (CD); administration of this strain has anti-inflammatory effects (27,28)
• Decrease in species of Bacteroides (27,28,29)
▪ Including "spatial reorganization" of its species
▪ Increased bacterial adhesion occurs (30)
• Decrease in species of <i>Bifidobacterium adolescentis</i> , <i>Dialister invisus</i> , and increase in frequency of <i>Ruminococcus gnavus</i> (27, 31)
• Decrease in species of <i>Roseburia hominis</i> , <i>Lactobacillus</i> , <i>Bifidobacterium</i> si <i>Akkermansia</i> (2, 32, 33)
• Overgrowth of sulphate-reducing bacterial species ( <i>Desulfovibrio</i> spp.), especially in patients with ulcerative colitis (UC) and pouchitis (27, 34)
• Increase in number of bacteria belonging to phylum Bacteroidetes (26, 35)
• Initiating role of chronic inflammation in overpopulation with species of Proteobacteria (26)
• Increase of pathogenic <i>E.coli</i> concentration, especially in ileal Crohn's Disease (26, 36)

*Adherent invasive Escherichia coli* (AIEC)-adhere and invade the epithelial cells. Prevalence of AIEC in ileal biopsies of patients with Crohn's disease is significantly higher than in control patients (36.4% vs. 6.2%) [40].

*Clostridium difficile* is incriminated in inflammatory disease flares, with rates varying widely between 5-60% [41]. Administration of immunosuppressive drugs increases the risk by 2-3 times. Currently, it is unclear whether *C. difficile* contributes to the intestinal inflammation characteristic of IBD or patients with such diseases are susceptible to infection with *C. difficile* [2].

*Campylobacter*-with its species, *ureolyticus* and *concisus*, alongside *jejuni*, can alter the intestinal barrier by translocation of commensal bacteria [2,42,43]. In a survey from 2011 [44] a several times increase in the risk of developing Crohn's disease was demonstrated in the first year, as well as the next 10 years, after acute infection with *C. jejuni*.

*Salmonella*. In a 2011 study [44] it was shown that infection with non-typhoid strains of *Salmonella* increases the risk of both ulcerative colitis and Crohn's disease in the first year after infection (5.4 times higher risk in the first year and 1.6 times in the next 10 years).

*Other microorganisms*. Epstein Barr virus can promote inflammation and increase multiplication in B lymphocytes [2,45]. Recently, the presence of *Fusobacterium varium* in significantly higher titre has been demonstrated in patients with UC [46]. Anti-*K. pneumoniae* antibodies are more common in patients with IBD (the severity of colonic inflammation increases in experimental models,

the expression of IL-1 $\beta$ , IL-6 and TNF- $\alpha$  increases) [26,47]. Other possibly involved microorganisms: CMV, *Candida albicans* - the exact role has not yet been established.

### SIBO and IBD

Causes of SIBO development in patients with IBD are multiple: postoperative absence of the ileo-cecal valve, presence of entero-colonic fistulas, motility disorders, intestinal strictures, alterations in the intestinal microbiome.

In current clinical practice, the use of respiratory H<sub>2</sub> tests presents high diagnostic accuracy, which is why it is commonly employed for highlighting SIBO.

In a 2009 study, Klaus et al [48] identified a prevalence of 25.3% of SIBO in patients with diagnosis of Crohn's disease, who reported an increase in the daily number of stools or flatulence. SIBO patients presented on average more stools/day (5.9 vs.3.7) and a lower body weight (63kg vs. 70kg). The association of SIBO was positive in patients with intestinal resection or mixed intestinal and colonic impairment, but no positive association with Crohn's disease activity index was found.

Changes in the treatment of IBD in recent years have led to the assumption that biological or immunosuppressive medication may increase the risk of infections. Regarding the risk of intestinal bacterial overgrowth, the assumption has recently been refuted; overall prevalence of SIBO in patients in remission was 16.8%, with no noticeable differences between patients under immunosuppressive, biological or mixed treatment [49].

When using H<sub>2</sub> glucose and lactulose breath tests to highlight SIBO and oro-cecal transit time, one can observe that the oro-cecal transit time was significantly higher in patients with CD compared to those with UC, and the prevalence of SIBO is higher in patients with CD (45.2%) compared to those with UC (17.8%) [50].

Similar data have been reported in a very recent study [51]: when using HGBT, prevalence of SIBO in patients with IBD is 20.6%, higher in CD versus UC (30.2% vs. 14.1%).

## Influencing the Intestinal Microbiome as a Treatment Modality in IBD

### *The role of probiotics*

There are few data in the Cochrane database regarding probiotic efficiency in CD [27]; Lactobacillus GG seems ineffective as an adjunct to standard medication in maintaining clinical remission in CD [52]. It appears that Saccharomyces boulardii could have a positive improvement effect on maintaining the permeability of the intestinal barrier [28,53].

In the case of UC, a mix of probiotics called VSL # 3 (Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus paracasei, Lactobacillus bulgaricus, Streptococcus thermophilus) proved effective as adjuvant therapy in maintaining remission, as well as in prevention of pouchitis [27,54]. Similar results were obtained for E. coli Nissle 1917 [55].

### *The role of prebiotics*

Administration of fructo-oligosaccharide in patients with CD apparently has no clinical benefits [56], but was associated with a significant reduction in Harvey Bradshaw index and an increase in faecal bifidobacteria concentration [57].

As for UC, different prebiotics proved a certain degree of efficiency: Germinated barley foodstuff and Ispaghula husk are effective in inducing remission in patients with moderate to severe UC [27,58,59]; oligofructose combination with inulin seems to reduce the degree of inflammation [60]; inulin reduces inflammation in pouchitis [61].

### *The role of antibiotics*

There are numerous data in the literature concerning the effectiveness of metronidazole and ciprofloxacin in the treatment of pouchitis and CD, as well as in UC.

Rifaximin (an antimicrobial agent active in the intestinal lumen) appears to be effective in inducing remission in patients with moderately active CD (remission rates of up to 62% in week 12) [62].

### *Helminth therapy*

Colonization with live strains or extracts of Schistosoma mansoni or Hymenolepis diminuta appear to exert effects against chronic colitis [2, 63], while Trichuris suis and Necator americanus could have therapeutic potential in IBD [2,64,65].

### *Faecal microbiota transplantation*

It is a relatively safe treatment modality in diseases like C. difficile infection (efficiency up to 92%) and IBD (there are reports in the literature of efficiency from 0% to 76%) (2,66). It is not however recommended in cases with important intestinal inflammation [2].

## Conclusions

Involvement of the intestinal microbiome in the aetiology of IBD is an area of great interest, likely to be elucidated in the coming years. Presence of SIBO to a quite important extent creates the possibility of using H<sub>2</sub> breath tests to identify the patients who could benefit from influencing the intestinal microbiome.

### **Acknowledgement:**

This paper is supported by the Sectoral Operational Programme Human Resources Development (SOP HRD), financed from the European Social Fund and by the Romanian Government under the contract number POSDRU/159/1.5/S/137390

Conflict of interests: none declared

### **References**

1. Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, et al. (2010) A human gut microbial gene catalogue established by metagenomic sequencing. Nature 464: 59-65.
2. Jin D, Zhang H, Sun J (2014) Manipulation of Microbiome, a Promising Therapy for Inflammatory Bowel Diseases. J Clin Cell Immunol 5: 234. doi:10.4172/2155-9899.1000234
3. O'Hara AM, Shanahan F (2006) The gut flora as a forgotten organ. EMBO Rep 7: 688-693.
4. Turnbaugh PJ, Ley RE, Hamady M, Fraser-Liggett CM, Knight R, et al. (2007) The human microbiome project. Nature 449: 804-810
5. John K. DiBaise. Nutritional Consequences of Small Intestinal Bacterial Overgrowth. PRACTICAL GASTROENTEROLOGY • DECEMBER 2008
6. Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. Nature, 2006;444:1022-1023.
7. DiBaise JK, Zhang H, Crowell MD, et al. Gut microbiota and its possible relationship to obesity. Mayo Clin Proc, 2008;83:460- 469.

8. Eckburg PB, Bik EM, Bernstein CN, Purdom E, Dethlefsen L, et al. (2005). Diversity of the human intestinal microbial flora. *Science* 308: 1635-1638
9. Sokol H, Pigneur B, Watterlot L, Lakhdari O, Bermúdez-Humarán LG, et al. (2008) *Faecalibacterium prausnitzii* is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. *Proc Natl Acad Sci U S A* 105: 16731-16736.
10. Seamus O'Mahony, Fergus Shanahan. Enteric Microbiota and Small Intestinal Bacterial Overgrowth. In „Sleisenger and Fordtran's Gastrointestinal and Liver Disease”, Ninth Edition, Saunders Elsevier 2010.
11. Salem A, Ronald BC (2014) Small Intestinal Bacterial Overgrowth (SIBO). *J Gastroint Dig Syst* 4: 225. doi:10.4172/2161-069X.1000225
12. S. C. Shah, L. W. Day, M. Somsouk, J. L. Sewell. Meta-analysis: antibiotic therapy for small intestinal bacterial overgrowth. *Aliment Pharmacol Ther* 2013; 38: 925–934
13. Bures J, Cyrany J, Kohoutova D, et al. Small intestinal bacterial overgrowth syndrome. *World J Gastroenterol* 2010;16: 2978–90
14. E. Grace, C. Shaw, K. Whelan, H. J. N. Andreyev. Small Intestinal Bacterial Overgrowth. Prevalence, Clinical Features, Current and Developing Diagnostic Tests, and Treatment. *Aliment Pharmacol Ther.* 2013;38(7):674-688
15. Stotzer PO, Johansson C, Mellstrom D, Lindstedt G, Kilander AF. Bone mineral density in patients with small intestinal bacterial overgrowth. *HepatoGastroenterology* 2003; 50: 1415–8.
16. Saltzman JR, Kowdley KV, Pedrosa MC, Sepe T, Golner B, Perrone G, et al. Bacterial overgrowth without clinical malabsorption in elderly hypochlorhydric subjects. *Gastroenterology* 1994; 106: 615–23.
17. Khoshini R, Dai SC, Lezcano S, Pimentel M. A systematic review of diagnostic tests for small intestinal bacterial overgrowth. *Dig Dis Sci* 2008; 53: 1443–54.
18. Husebye E (2005) The pathogenesis of gastrointestinal bacterial overgrowth. *Chemotherapy* 51 Suppl 1: 1-22.
19. Bohm M, Siwiec RM, Wo JM (2013) Diagnosis and management of small intestinal bacterial overgrowth. *Nutr Clin Pract* 28: 289-299.
20. Alexander Eisenmann, Anton Amann, Michael Said, Bettina Datta, Maximilian Ledochowski. Implementation and interpretation of hydrogen breath tests. *J. Breath Res.* 2 (2008) 046002
21. Gasbarrini AA, Corazza GRG, Gasbarrini GG, Montalto MM, Di Stefano MM, Basilisco GG, et al. Methodology and indications of H2-breath testing in gastrointestinal diseases: The Rome Consensus Conference. *Aliment Pharmacol Ther* 2009; 29(Suppl. 1): 1–49
22. Khor B, Gardet A, Xavier RJ: Genetics and pathogenesis of inflammatory bowel disease. *Nature* 2011, 474:307-317.
23. Xochitl C Morgan, Timothy L Tickle, Harry Sokol, Dirk Gevers, Kathryn L Devaney, Doyle V Ward, Joshua A Reyes, Samir A Shah, Neal LeLeiko, Scott B Snapper, Athos Bousvaros, Joshua Korzenik, Bruce E Sands, Ramnik J Xavier and Curtis Huttenhower. Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. *Morgan et al. Genome Biology* 2012, 13:R79
24. Elson CO, Cong Y, McCracken VJ et al. Experimental models of inflammatory bowel disease reveal innate, adaptive and regulatory mechanisms of host dialogue with microbiota. *Immunol Rev* 2005, 206:270-6
25. R. K. Sellon, S. Tonkonogy, M. Schultz et al., “Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice,” *Infection and Immunity*, vol. 66, no. 11, pp. 5224–5231, 1998
26. Hold GL, Smith M, Grange C, Watt ER, El-Omar EM, Mukhopadhyay I. Role of the gut microbiota in inflammatory bowel disease pathogenesis: What have we learnt in the past 10 years? *World J Gastroenterol* 2014; 20(5): 1192-1210
27. Franco Scaldaferrri, Viviana Gerardi, Loris Riccardo Lopetuso, Fabio Del Zompo, Francesca Mangiola, Ivo Boškoski, Giovanni Bruno, Valentina Petito,1 Lucrezia Laterza, Giovanni Cammarota, Eleonora Gaetani, Alessandro Sgambato, and Antonio Gasbarrini. Gut Microbial Flora, Probiotics, and Probiotics in IBD: Their Current Usage and Utility. *BioMed Research International Volume* 2013, Article ID 435268, 9 pages. <http://dx.doi.org/10.1155/2013/435268>
28. H. Sokol, B. Pigneur, L. Watterlot et al., “*Faecalibacterium prausnitzii* is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 105, no. 43, pp. 16731–16736, 2008.
29. C.Manichanh, N. Borrueal, F. Casellas, and F. Guarner, “The gut microbiota in IBD,” *Nature Reviews*, vol. 9, no. 10, pp. 599–608, 2012.
30. Swidsinski A, Weber J, Loening-Baucke V, Hale LP, Lochs H. Spatial organization and composition of the mucosal flora in patients with inflammatory bowel disease. *J Clin Microbiol* 2005; 43: 3380-3389 [PMID: 16000463 DOI: 10.1128/JCM.43.7.3380-3389.2005
31. M. Joossens, G. Huys, M. Cnockaert et al., “Dysbiosis of the faecal microbiota in patients with Crohn’s disease and their unaffected relatives,” *Gut*, vol. 60, no. 5, pp. 631–637, 2011
32. Shanahan F (2012) The colonic microbiota and colonic disease. *Curr Gastroenterol Rep* 14: 446-452.
33. Machiels K, Joossens M, Sabino J, De Preter V, Arijis I, et al. (2013) A decrease of the butyrate-producing species *Roseburia hominis* and *Faecalibacterium prausnitzii* defines dysbiosis in patients with ulcerative colitis. *Gut* 63: 1275-1283.
34. F. Rowan, N. G. Docherty, M. Murphy, B. Murphy, J. C. Coffey, and P. R. O’Connell, “*Desulfovibrio* bacterial species are increased in ulcerative colitis,” *Diseases of the Colon and Rectum*, vol. 53, no. 11, pp. 1530–1536, 2010

35. Andoh A, Kuzuoka H, Tsujikawa T, Nakamura S, Hirai F, Suzuki Y, Matsui T, Fujiyama Y, Matsumoto T. Multicenter analysis of fecal microbiota profiles in Japanese patients with Crohn's disease. *J Gastroenterol* 2012; 47: 1298-1307 [PMID: 22576027 DOI: 10.1007/s00535-012-0605-0]
36. Darfeuille-Michaud A, Neut C, Barnich N, Lederman E, Di Martino P, Desreumaux P, Gambiez L, Joly B, Cortot A, Colombel JF. Presence of adherent *Escherichia coli* strains in ileal mucosa of patients with Crohn's disease. *Gastroenterology* 1998; 115: 1405-1413 [PMID: 9834268 DOI: 10.1016/S0016-5085(98)70019-8]
37. Tuci A, Tonon F, Castellani L, Sartini A, Roda G, et al. (2011) Fecal detection of *Mycobacterium avium* paratuberculosis using the IS900 DNA sequence in Crohn's disease and ulcerative colitis patients and healthy subjects. *Dig Dis Sci* 56: 2957-2962.
38. Lee A, Griffiths TA, Parab RS, King RK, Dubinsky MC, et al. (2011) Association of *Mycobacterium avium* subspecies paratuberculosis with Crohn Disease in pediatric patients. *J Pediatr Gastroenterol Nutr* 52: 170-174.
39. Jergens AE, Wilson-Welder JH, Dorn A, Henderson A, Liu Z, Evans RB, Hostetter J, Wannemuehler MJ. *Helicobacter bilis* triggers persistent immune reactivity to antigens derived from the commensal bacteria in gnotobiotic C3H/HeN mice. *Gut* 2007; 56: 934-940 [PMID: 17145736 DOI: 10.1136/gut.2006.099242]
40. Martinez-Medina M, Aldeguer X, Lopez-Siles M, González-Huix F, López-Oliu C, Dahbi G, Blanco JE, Blanco J, Garcia-Gil LJ, Darfeuille-Michaud A. Molecular diversity of *Escherichia coli* in the human gut: new ecological evidence supporting the role of adherent-invasive *E. coli* (AIEC) in Crohn's disease. *Inflamm Bowel Dis* 2009; 15: 872-882 [PMID: 19235912 DOI: 10.1002/ibd.20860]
41. Reddy SS, Brandt LJ (2013) *Clostridium difficile* infection and inflammatory bowel disease. *J Clin Gastroenterol* 47: 666-671
42. Kalischuk LD, Buret AG (2010) A role for *Campylobacter jejuni*-induced enteritis in inflammatory bowel disease? *Am J Physiol Gastrointest Liver Physiol* 298: G1-9.
43. Kalischuk LD, Inglis GD, Buret AG (2009) *Campylobacter jejuni* induces transcellular translocation of commensal bacteria via lipid rafts. *Gut Pathog* 1: 2.
44. Jess T, Simonsen J, Nielsen NM, Jørgensen KT, Bager P, et al. (2011) Enteric *Salmonella* or *Campylobacter* infections and the risk of inflammatory bowel disease. *Gut* 60: 318-324.
45. Sankaran-Walters S, Ransibrahmanakul K, Grishina I, Hung J, Martinez E, et al. (2011) Epstein-Barr virus replication linked to B cell proliferation in inflamed areas of colonic mucosa of patients with inflammatory bowel disease. *J Clin Virol* 50: 31-36.
46. Ohkusa T, Okayasu I, Ogihara T, Morita K, Ogawa M, Sato N. Induction of experimental ulcerative colitis by *Fusobacterium varium* isolated from colonic mucosa of patients with ulcerative colitis. *Gut* 2003; 52: 79-83 [PMID: 12477765 DOI:10.1136/gut.52.1.79]
47. Lee IA, Kim DH. *Klebsiella pneumoniae* increases the risk of inflammation and colitis in a murine model of intestinal bowel disease. *Scand J Gastroenterol* 2011; 46: 684-693 [PMID: 21410316 DOI: 10.3109/00365521.2011.560678]
48. Jochen Klaus, Ulrike Spaniol, Guido Adler, Richard A Mason, Max Reinshagen and Christian von Tirpitz C. Small intestinal bacterial overgrowth mimicking acute flare as a pitfall in patients with Crohn's Disease. *BMC Gastroenterology* 2009, 9:61 doi:10.1186/1471-230X-9-61
49. Sánchez-Montes C, Ortiz V, Bastida G, Rodríguez E, Yago M, Beltrán B, Aguas M, Iborra M, Garrigues V, Ponce J, Nos P. Small intestinal bacterial overgrowth in inactive Crohn's disease: Influence of thiopurine and biological treatment. *World J Gastroenterol* 2014; 20(38): 13999-14003 Available from: URL: <http://www.wjgnet.com/1007-9327/full/v20/i38/13999.htm> DOI: <http://dx.doi.org/10.3748/wjg.v20.i38.13999>
50. Rana SV, Sharma S, Malik A, Kaur J, Prasad KK, Sinha SK, Singh K. Small intestinal bacterial overgrowth and orocecal transit time in patients of inflammatory bowel disease. *Dig Dis Sci*. 2013 Sep;58(9):2594-8. doi: 10.1007/s10620-013-2694-x. Epub 2013 May 7.
51. Ji Min Lee, Kang-Moon Lee, Yoon Yung Chung, Yang Woon Lee, Dae Bum Kim, Hea Jung Sung, Woo Chul Chung and Chang-Nyol Paik. Clinical Significance of the Glucose Breath Test in Patients with Inflammatory Bowel Disease. In Press. DOI: 10.1111/jgh.12908
52. M. Schultz, A. Timmer, H. H. Herfarth, R. B. Sartor, J. A. Vanderhoof, and H. C. Rath, "LactobacillusGGin inducing and maintaining remission of Crohn's disease," *BMC Gastroenterology*, vol. 4, article 5, 2004
53. E. Garcia Vilela, M. De Lourdes De Abreu Ferrari, H. Oswaldo Da Gama Torres et al., "Influence of *Saccharomyces boulardii* on the intestinal permeability of patients with Crohn's disease in remission," *Scandinavian Journal of Gastroenterology*, vol. 43, no. 7, pp. 842-848, 2008.
54. G. R. Veerappan, J. Betteridge, and P. E. Young, "Probiotics for the treatment of inflammatory bowel disease," *Current Gastroenterology Reports*, vol. 14, no. 4, pp. 324-333, 2012
55. Schultz M. Clinical use of *E. coli* Nissle 1917 in inflammatory bowel disease. *Inflamm Bowel Dis* 2008; 14: 1012-1018 [PMID: 18240278 DOI: 10.1002/ibd.20377]
56. Lindsay JO, Whelan K, Stagg AJ, Gobin P, Al-Hassi HO, Rayment N, Kamm MA, Knight SC, Forbes A. Clinical, microbiological, and immunological effects of fructo-oligo- Hold GL et al. Role of gut microbiota in IBD *WJG*[[www.wjgnet.com](http://www.wjgnet.com) 1210 February 7, 2014][Volume 20|Issue 5] saccharide in patients with Crohn's disease. *Gut* 2006; 55: 348-355 [PMID: 16162680 DOI: 10.1136/gut.2005.074971]
57. Damaskos D, Kolios G. Probiotics and prebiotics in inflammatory bowel disease: microflora 'on the scope'. *Br J Clin Pharmacol* 2008; 65: 453-467 [PMID: 18279467 DOI: 10.1111/j.1365-2125.2008.03096.x]

58. O. Kanauchi, T. Suga, M. Tojihara et al., "Treatment of ulcerative colitis by feeding with germinated barley foodstuff: first report of a multicenter open control trial," *Journal of Gastroenterology*, vol. 37, no. 14, pp. 67–72, 2002.
59. C. Hallert, M. Kaldma, and B.-G. Petersson, "Ispaghula husk may relieve gastrointestinal symptoms in ulcerative colitis in remission," *Scandinavian Journal of Gastroenterology*, vol. 26, no. 7, pp. 747–750, 1991.
60. F. Casellas, N. Borrueal, A. Torrejón et al., "Oral oligofructose-enriched inulin supplementation in acute ulcerative colitis is well tolerated and associated with lowered faecal calprotectin," *Alimentary Pharmacology and Therapeutics*, vol. 25, no. 9, pp. 1061–1067, 2007.
61. C. F. M. Welters, E. Heineman, F. B. J. M. Thunnissen, A. E. J. M. Van den Bogaard, P. B. Soeters, and C. G. M. I. Baeten, "Effect of dietary inulin supplementation on inflammation of pouch mucosa in patients with an ileal pouch-anal anastomosis," *Diseases of the Colon and Rectum*, vol. 45, no. 5, pp. 621–627, 2002.
62. COSIMO PRANTERA, HERBERT LOCHS, MARIA GRIMALDI, SILVIO DANESE, MARIA LIA SCRIBANO, PAOLO GIONCHETTI, on Behalf of the Retic Study Group. Rifaximin-Extended Intestinal Release Induces Remission in Patients With Moderately Active Crohn's Disease. *GASTROENTEROLOGY* 2012;142:473–481
63. Ruysers NE, De Winter BY, De Man JG, Loukas A, Pearson MS, et al. (2009) Therapeutic potential of helminth soluble proteins in TNBS induced colitis in mice. *Inflamm Bowel Dis* 15: 491-500.
64. Weinstock JV, Elliott DE (2013) Translatability of helminth therapy in inflammatory bowel diseases. *Int J Parasitol* 43: 245-251. 163.
65. Schölmerich J (2013) Trichuris suis ova in inflammatory bowel disease. *Dig Dis* 31: 391-395.
66. Anderson JL, Edney RJ, Whelan K (2012) Systematic review: faecal microbiota transplantation in the management of inflammatory bowel disease. *Aliment Pharmacol Ther* 36: 503-516.

---

*Corresponding Author: M. Andrei, Department of Gastroenterology, Hepatology and Digestive Endoscopy, Elias Emergency Hospital, 17 Marasti street, district 1, Bucharest, Romania; e-mail: mihai1984@gmail.com*